Biogen Inc.
Revenue Breakdown
| Fiscal Year | TECFIDERA | Interferon (AVONEX+PLEGRIDY combined) | AVONEX | PLEGRIDY | TYSABRI | FAMPYRA | ZINBRYTA | VUMERITY | ELOCTATE | ALPROLIX | FUMADERM | SPINRAZA | ADUHELM | BENEPALI | IMRALDI | FLIXABI | BYOOVIZ | TOFIDENCE | QALSODY | SKYCLARYS | ZURZUVAE | FUMADERM and ADUHELM (combined) | Other Product Revenue | Revenue from anti-CD20 therapeutic programs | Alzheimer's collaboration revenue | Contract manufacturing, royalty and other revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $679.7M | — | $695.5M | $250.1M | $1.67B | $1.4M | — | $746.8M | — | — | — | $1.55B | — | $453.2M | $190.2M | $52.6M | $32.4M | $700.0K | $86.9M | $520.5M | $195.1M | $2.1M | — | $1.86B | $177.7M | $732.9M |